Considerations and perspectives on phage therapy from the transatlantic taskforce on antimicrobial resistance
Amid rising antimicrobial resistance and limited antibiotic innovation, bacteriophages are gaining attention as potential therapeutics across human health, animal, and food sectors. Despite historical use, their clinical application in humans remains constrained by scientific, industrial, and regulatory challenges. To address these issues, the Transatlantic Task Force on Antimicrobial Resistance (TATFAR) convened sessions with experts from member parties. This perspective synthesizes insights from the TATFAR group, highlighting regulatory differences, research gaps, and opportunities for international collaborations to advance bacteriophage therapy.
Authors
- Kyung D. Moon (ORCID: https://orcid.org/0000-0001-5809-1601)
- Marco Cavaleri (ORCID: https://orcid.org/0000-0001-8246-755X)
- Carmen Coxon (ORCID: https://orcid.org/0000-0001-8694-4894)
- Radu Botgros
- Sarah Djebara
- Christine Årdal (ORCID: https://orcid.org/0000-0002-0891-0549)
- Cara R. Fiore
- Laura Durno
- J Perrin
- Dennis M. Dixon
Institutions
- Health Canada (CA)
- European Medicines Agency (NL)
- National Institutes of Health (US)
- Center for Biologics Evaluation and Research (US)
- European Union (BE)
- Norwegian Institute of Public Health (NO)
- University of Hertfordshire (GB)
- Directorate-General for Health and Food Safety (BE)
- Queen Astrid Military Hospital (BE)
- National Institute of Allergy and Infectious Diseases (US)
Publication Details
- Journal
- Nature Communications
- Published
- 2025-12-04
- DOI
- https://doi.org/10.1038/s41467-025-64608-3
- Citations
- 10
- Primary Topic
- Bacteriophages and microbial interactions
- Type
- article
- Field-Weighted Citation Impact
- 17.16